Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBITDA Margin (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBITDA Margin for 11 consecutive years, with 415.97% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 60617.0% to 415.97% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 609.22% through Dec 2025, up 28628.0% year-over-year, with the annual reading at 609.22% for FY2025, 28628.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 415.97% at Intellia Therapeutics, up from 732.75% in the prior quarter.
  • The five-year high for EBITDA Margin was 220.83% in Q4 2021, with the low at 23935.0% in Q3 2021.
  • Average EBITDA Margin over 5 years is 2071.31%, with a median of 780.13% recorded in 2023.
  • The sharpest move saw EBITDA Margin plummeted -2380915bps in 2021, then skyrocketed 2308287bps in 2022.
  • Over 5 years, EBITDA Margin stood at 220.83% in 2021, then dropped by -28bps to 282.28% in 2022, then plummeted by -260bps to 1016.74% in 2023, then decreased by -1bps to 1022.14% in 2024, then surged by 59bps to 415.97% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 415.97%, 732.75%, and 713.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.